Adrian Rawcliffe, Adaptimmune CEO
September 9, 2022 10:30 AM EDTUpdated 10:51 AM
R&D
Cell/Gene Tx

#ES­MO22: Adap­ti­m­mune touts new PhI da­ta for its cell ther­a­py treat­ment

Tyler Patchen

News Reporter

As the cell ther­a­py biotech Adap­ti­m­mune has been ea­ger to present da­ta to progress with the FDA, the com­pa­ny hopes that its lat­est show­ing at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times